Research programme: neutralising antibody cocktail - Lumen Bioscience
Alternative Names: Camelid antibodies - Lumen Bioscience; Nanobodies - Lumen BioscienceLatest Information Update: 28 Sep 2020
At a glance
- Originator Lumen Bioscience
- Class Single-domain antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 24 Sep 2020 Lumen Bioscience and US Army Medical Research and Development Command agree to co-develop neutralising antibody cocktail for COVID-2019 infections
- 24 Sep 2020 Early research in COVID-2019 infections in USA (PO)
- 24 Sep 2020 Lumen Bioscience plans a phase II trial for COVID-2019 infections in May 2021 (PO)